Hello and welcome to my Nuzzel newsletter!
I'm Ronny, International Neuroendocrine Cancer Advocate. Independent Patient Voice. Award winning WEGO Health Patient Leader, Cure Today Contributor, Featured 1 million + Blogger, Veteran.
CLARINET FORTE is a prospective single-arm, open-label, exploratory, international Phase II study to explore the efficacy and safety of an increased Somatuline Autogel (lanreotide) dosing interval (120 mg every 14 days) in patients with metastatic…
The Pfizer vaccine appears to slow the spread of coronavirus as well as preventing people getting seriously ill, a study at a hospital has found. The findings support similar research by Public Health England and an Oxford-AstraZenica study…
Levels of coronavirus have continued to decrease across the UK, Office for National Statistics data shows. The figures, for the seven days up to 19 February, reveal around 421,300 people in the community with the virus. The infection rates are…
SIRT is a way of giving radiation treatment for cancer via tiny radioactive beads (called microspheres) that are injected into the artery supplying blood to the tumour via a catheter from the femoral artery. This helps to minimise the risk of…
The PanNET Working Group of the 16th International Multiple Endocrine Neoplasia Workshop (MEN2019) convened in Houston, TX, USA, 27–29 March 2019 to discuss key unmet clinical needs related to PanNET in the context of MEN1, with a special…
Share on facebook Facebook Share on twitter Twitter Share on pinterest Pinterest Share on whatsapp WhatsApp Share on email Email I realise some of you are busy but if you wanted a quick catch up and summary of what's currently relevant on my site…
Ronny Allan - Living with Neuroendocrine Cancer
–
Ronny Allan
– Jul 7, 2015, 7:00 AM
Although initially considered rare tumours up until 10 years ago, the most recent data indicates the incidence of NETs has increased exponentially over the last 4 decades and they are as common as Myeloma, Testicular Cancer, and Hodgkin's Lymphoma.
Headline in April 2019: Update from 2019 AACR Annual Meeting 'A combination of two common immunotherapy drugs shrinks rare, aggressive neuroendocrine tumors, according to new research results presented at the American Association for Cancer…
On Rare Disease Day, what's wrong with a bit of Neuroendocrine Cancer awareness? Well, there are three main things wrong with Neuroendocrine Cancer awareness: The incidence and prevalence of Neuroendocrine Neoplasms (the combination of…
